BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax of $33.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2026-06-30 was $33.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2026-03-31 was $54.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2025-06-30 was -$229.00M, a 372.62% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2025-03-31 was -$191.00M, a 175.20% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2025 was -$340.00M, a 168.69% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2024 was $495.00M, a 607.14% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2023 was $70.00M, a 88.03% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2022 was $585.00M, a 60.71% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.00M 10-Q · filed 2026-07-30 | $86.00M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $54.00M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | -$340.00M 10-K · filed 2026-02-11 | |||
| 2025-06-30 | -$229.00M 10-Q · filed 2026-07-30 | -$420.00M 10-Q · filed 2026-07-30 | -$104.00M derived: sum of 3 quarters · filed 2026-07-30 | -$263.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$191.00M 10-Q · filed 2026-04-30 | $125.00M derived: sum of 2 quarters · filed 2026-04-30 | -$34.00M derived: sum of 3 quarters · filed 2026-04-30 | $50.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $316.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $157.00M derived: sum of 2 quarters · filed 2026-02-11 | $241.00M derived: sum of 3 quarters · filed 2026-02-11 | $495.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$159.00M 10-Q · filed 2024-10-31 | -$75.00M derived: sum of 2 quarters · filed 2024-10-31 | $179.00M 10-Q · filed 2024-10-31 | $18.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $84.00M 10-Q · filed 2024-07-26 | $338.00M 10-Q · filed 2024-07-26 | $177.00M derived: sum of 3 quarters · filed 2026-02-11 | $327.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $254.00M 10-Q · filed 2025-04-24 | $93.00M derived: sum of 2 quarters · filed 2026-02-11 | $243.00M derived: sum of 3 quarters · filed 2026-02-11 | $337.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$161.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$11.00M derived: sum of 2 quarters · filed 2026-02-11 | $83.00M derived: sum of 3 quarters · filed 2026-02-11 | $70.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $150.00M 10-Q · filed 2024-10-31 | $244.00M derived: sum of 2 quarters · filed 2024-10-31 | $231.00M 10-Q · filed 2024-10-31 | -$290.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $94.00M 10-Q · filed 2024-07-26 | $81.00M 10-Q · filed 2024-07-26 | -$440.00M derived: sum of 3 quarters · filed 2025-02-12 | $65.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$13.00M 10-Q · filed 2024-04-25 | -$534.00M derived: sum of 2 quarters · filed 2025-02-12 | -$29.00M derived: sum of 3 quarters · filed 2025-02-12 | $452.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$521.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$16.00M derived: sum of 2 quarters · filed 2025-02-12 | $465.00M derived: sum of 3 quarters · filed 2025-02-12 | $585.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $505.00M 10-Q · filed 2023-10-26 | $986.00M derived: sum of 2 quarters · filed 2023-10-26 | $1.11B 10-Q · filed 2023-10-26 | $1.16B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $481.00M 10-Q · filed 2023-07-27 | $601.00M 10-Q · filed 2023-07-27 | $651.00M derived: sum of 3 quarters · filed 2024-02-13 | $744.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $120.00M 10-Q · filed 2023-04-27 | $170.00M derived: sum of 2 quarters · filed 2024-02-13 | $263.00M derived: sum of 3 quarters · filed 2024-02-13 | $225.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $143.00M derived: sum of 2 quarters · filed 2024-02-13 | $105.00M derived: sum of 3 quarters · filed 2024-02-13 | $364.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $93.00M 10-Q · filed 2022-10-26 | $55.00M derived: sum of 2 quarters · filed 2022-10-26 | $314.00M 10-Q · filed 2022-10-26 | $163.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$38.00M 10-Q · filed 2022-07-27 | $221.00M 10-Q · filed 2022-07-27 | $70.00M derived: sum of 3 quarters · filed 2023-02-14 | -$58.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $259.00M 10-Q · filed 2022-04-29 | $108.00M derived: sum of 2 quarters · filed 2023-02-14 | -$20.00M derived: sum of 3 quarters · filed 2023-02-14 | -$54.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$151.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$279.00M derived: sum of 2 quarters · filed 2023-02-14 | -$313.00M derived: sum of 3 quarters · filed 2023-02-14 | -$216.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$128.00M 10-Q · filed 2021-10-27 | -$162.00M derived: sum of 2 quarters · filed 2021-10-27 | -$65.00M 10-Q · filed 2021-10-27 | -$102.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | -$34.00M 10-Q · filed 2021-07-28 | $63.00M 10-Q · filed 2021-07-28 | $26.00M derived: sum of 3 quarters · filed 2022-02-09 | $89.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $97.00M 10-Q · filed 2021-04-29 | $60.00M derived: sum of 2 quarters · filed 2022-02-09 | $123.00M derived: sum of 3 quarters · filed 2022-02-09 | $117.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | -$37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $26.00M derived: sum of 2 quarters · filed 2022-02-09 | $20.00M derived: sum of 3 quarters · filed 2022-02-09 | $65.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $63.00M 10-Q · filed 2020-11-05 | $57.00M derived: sum of 2 quarters · filed 2020-11-05 | $102.00M 10-Q · filed 2020-11-05 | $125.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | -$6.00M 10-Q · filed 2020-08-06 | $39.00M 10-Q · filed 2020-08-06 | $62.00M derived: sum of 3 quarters · filed 2021-02-10 | $80.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $45.00M 10-Q · filed 2020-05-07 | $68.00M derived: sum of 2 quarters · filed 2021-02-10 | $86.00M derived: sum of 3 quarters · filed 2021-02-10 | $169.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $41.00M derived: sum of 2 quarters · filed 2021-02-10 | $124.00M derived: sum of 3 quarters · filed 2021-02-10 | $86.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $18.00M 10-Q · filed 2019-10-31 | $101.00M derived: sum of 2 quarters · filed 2019-10-31 | $63.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $83.00M 10-Q · filed 2019-07-25 | $45.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | -$38.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | -$101.00M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | -$5.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |